Annexon Inc (ANNX NASDAQ) stock market data APIs
$3.1721
0.04(1.3%)
as of November 3, 2025
Try our APIs with
free plan!
Annexon Inc Financial Data Overview
Price chart is built with
Anychart
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Prev. Close
3.1721
Open
3.2134
High
3.3701
Low
3.0749
52 wk Range
1.285-7.625
Market Cap
347 M
Shares Outstanding
110 M
EPS
-0.34
Beta
1.366
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Annexon Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Annexon Inc data using free add-ons & libraries
Get Annexon Inc Fundamental Data
Annexon Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -198 900 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.36
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Annexon Inc News
New
Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition
Annexon, Inc. (NASDAQ:ANNX) is among the best fast money stocks to buy now. During the first quarter, Nuveen LLC acquired a new position in Annexon, Inc. (NASDAQ:ANNX) through the purchase of 23,491 s...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with deva...
Annexon Narrows Loss in Fiscal Q2
Key Points Annexon reported a GAAP net loss per share of $0.34 for Q2 2025, narrower than the consensus GAAP estimate of $(0.37). Research and development expenses climbed 76.8% year over year (GAAP)...
Annexon Biosciences GAAP EPS of -$0.34 beats by $0.03
* Annexon Biosciences press release [https://seekingalpha.com/pr/20201908-annexon-reports-second-quarter-2025-financial-results-portfolio-progress-and-key-anticipated] (NASDAQ:ANNX [https://seekinga...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
